In metrology, measuring sticks must be traceably calibrated against standard tools of measurement, which must further be traced to primary standards based on physical constants, such as units of wavelength of light that have
low measures of uncertainty.
Not exact matches
These risks and
uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity
measures in European countries that may increase the amount
of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability
of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction
of generic versions
of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect
of lowering prices or reducing the number
of insured patients; the possibility
of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels
of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits
of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages
of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development
of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate
of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).
But «it is likely that the
uncertainty surrounding the presidential election had a negative impact, especially among
lower income consumers, and without that added
uncertainty, the confidence
measures may not have weakened,» said Richard Curtin, the leading economist
of the University
of Michigan's preliminary consumer confidence survey.
Institutional investors may be scratching their heads at why the widely watched
measure of market concern known colloquially as the «fear index,» or VIX, recently reached a 23 - year
low despite plenty
of reasons for the sort
of uncertainty that makes markets jittery.
A: Every investor will have to make their own judgment about the market, it does seem like
measures of volatility are relatively
low given all the
uncertainties at present.
The GALLEX experiment
measures a
low flux
of solar neutrinos, but with such large
uncertainties that, again, theresult could be consistent with the predictions
of the new solar models.
Based on the rather vast
uncertainties in aerosol forcing, and the substantial discrepancies between model projections
of ocean heat uptake and
measured heat uptake (ARGO), it strikes me as bizarre that the IPCC insists on excluding the possibility
of quite
low sensitivity, when there is a wealth
of evidence for fairly
low sensitivity.
It's correct to take the precautionary principle into account in the estimate
of the damages giving more weight to the unfavorable outcomes than to the favorable, but the
uncertainties in the efficiency
of the mitigating
measures should be also taken into account and taken them into account means that the correct level
of tax is
lower than it would be without this
uncertainty.
The shading indicates a
measure of uncertainty about future sea level for two different scenarios — a
low emissions scenario where carbon emissions are rapidly cut (blue RCP 2.6) and a high emissions scenario with no carbon cuts (red RCP 8.5).
The hope
of the industry was that RSD would provide a rapidly deployable method for
measuring power performance that would also result in a
lower uncertainty due to having measurements across the entire turbine rotor.
The first big issue is about the accuracy
of estimations: (a) there are discordant trends
of present:
low atmospheric satellite
measured temperature vs. GST
measured in land & oceans; (b) there is a big
uncertainty linked to the proxy data obtained during XX, XIX and beyond centuries.